Atezolizumab - Genentech

Drug Profile

Atezolizumab - Genentech

Alternative Names: Anti-PDL-1-Genentech/Roche; MPDL-3280A; RG-7446; RO 5541267; TECENTRIQ

Latest Information Update: 16 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genentech; University Medical Center Groningen
  • Developer ARCAGY/GINECO Group; Astex Pharmaceuticals; BioLineRx; Chugai Pharmaceutical; Clovis Oncology; Columbia University; Dana-Farber Cancer Institute; European Organisation for Research and Treatment of Cancer; Exelixis; Fondazione Michelangelo; Genentech; Gradalis; Immune Design; Incyte Corporation; M. D. Anderson Cancer Center; National Cancer Institute (USA); Roche; University Medical Center Groningen; University of California at San Francisco; University of California System; Yale University
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD274 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer; Urogenital cancer
  • Registered Bladder cancer
  • Phase III Breast cancer; Colorectal cancer; Fallopian tube cancer; Malignant melanoma; Ovarian cancer; Peritoneal cancer; Prostate cancer; Renal cell carcinoma; Small cell lung cancer
  • Phase II Brain metastases; Chronic lymphocytic leukaemia; Gynaecological cancer; MALT lymphoma; Mantle-cell lymphoma; Soft tissue sarcoma; Solid tumours; Thyroid cancer; Waldenstrom's macroglobulinaemia
  • Phase I/II Acute myeloid leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Glioblastoma; Pancreatic cancer
  • Phase I Multiple myeloma; Myelodysplastic syndromes
  • No development reported Haematological malignancies

Most Recent Events

  • 03 Oct 2017 Kite Pharma has been acquired by Gilead Sciences
  • 29 Sep 2017 Phase-I/II clinical trials in Acute myeloid leukaemia (Combination therapy, In the elderly) in USA (IV)
  • 22 Sep 2017 Registered for Bladder cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Norway, Liechtenstein, Iceland, European Union (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top